It is very common for a generic first filer to "sell" their first 6 month exclusive rights via settling the patent case. It is always a win-win if they can come to terms. The relatively modest amount would indicate TEVA was not all that confident of winning the court case and AMRN stood their ground.
If any of Ready or the others elect to launch at risk come next summer, TEVA will follow suit.
The court case is likely more important than the FDA delay.
Market Data 
Markets 
AI
